マントル細胞リンパ腫治療法の世界市場:併用療法、単独療法...市場調査レポートについてご紹介

【英文タイトル】Global Mantle Cell Lymphoma Therapeutics Market 2019-2023

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Combination therapy – Market size and forecast 2018-2023

Monotherapy – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Advent of novel therapies

Research grants and funding

Special drug designations

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Allergan Plc

AstraZeneca Plc

Celgene Corp.

Johnson & Johnson Services Inc.

Takeda Pharmaceutical Co. Ltd.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Product – Market share 2018-2023 (%)

Exhibit 19: Comparison by product

Exhibit 20: Combination therapy – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Combination therapy – Year-over-year growth 2019-2023 (%)

Exhibit 22: Monotherapy – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Monotherapy – Year-over-year growth 2019-2023 (%)

Exhibit 24: Market opportunity by product

Exhibit 25: Customer landscape

Exhibit 26: Market share by geography 2018-2023 (%)

Exhibit 27: Geographic comparison

Exhibit 28: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 29: North America – Year-over-year growth 2019-2023 (%)

Exhibit 30: Top 3 countries in North America

Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 33: Top 3 countries in Europe

Exhibit 34: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 35: Proportion of geriatric population in Asia 2007 and 2017

Exhibit 36: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 37: Top 3 countries in Asia

Exhibit 38: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 39: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 40: Top 3 countries in ROW

Exhibit 41: Key leading countries

Exhibit 42: Market opportunity

Exhibit 43: Pipeline molecules

Exhibit 44: Growth in geriatric population 2013-2017 (%)

Exhibit 45: Side effects of drugs treating mantle cell lymphoma

Exhibit 46: Impact of drivers and challenges

Exhibit 47: Drug designations

Exhibit 48: Recently approved drug designations to drug candidates aimed to treat mantle cell lymphoma

Exhibit 49: Vendor landscape

Exhibit 50: Landscape disruption

Exhibit 51: Vendors covered

Exhibit 52: Vendor classification

Exhibit 53: Market positioning of vendors

Exhibit 54: Allergan Plc – Vendor overview

Exhibit 55: Allergan Plc – Business segments

Exhibit 56: Allergan Plc – Organizational developments

Exhibit 57: Allergan Plc – Geographic focus

Exhibit 58: Allergan Plc – Segment focus

Exhibit 59: Allergan Plc – Key offerings

Exhibit 60: Allergan Plc – Key customers

Exhibit 61: AstraZeneca Plc – Vendor overview

Exhibit 62: AstraZeneca Plc – Product segments

Exhibit 63: AstraZeneca Plc – Organizational developments

Exhibit 64: AstraZeneca Plc – Geographic focus

Exhibit 65: AstraZeneca Plc – Key offerings

Exhibit 66: AstraZeneca Plc – Key customers

Exhibit 67: Celgene Corp. – Vendor overview

Exhibit 68: Celgene Corp. – Business segments

Exhibit 69: Celgene Corp. – Organizational developments

Exhibit 70: Celgene Corp. – Geographic focus

Exhibit 71: Celgene Corp. – Key offerings

Exhibit 72: Celgene Corp. – Key customers

Exhibit 73: Johnson & Johnson Services, Inc. – Vendor overview

Exhibit 74: Johnson & Johnson Services, Inc. – Business segments

Exhibit 75: Johnson & Johnson Services, Inc. – Organizational developments

Exhibit 76: Johnson & Johnson Services, Inc. – Geographic focus

Exhibit 77: Johnson & Johnson Services, Inc. – Segment focus

Exhibit 78: Johnson & Johnson Services, Inc. – Key offerings

Exhibit 79: Johnson & Johnson Services, Inc. – Key customers

Exhibit 80: Takeda Pharmaceutical Co. Ltd. – Vendor overview

Exhibit 81: Takeda Pharmaceutical Co. Ltd. – Business segments

Exhibit 82: Takeda Pharmaceutical Co. Ltd. – Organizational developments

Exhibit 83: Takeda Pharmaceutical Co. Ltd. – Geographic focus

Exhibit 84: Takeda Pharmaceutical Co. Ltd. – Key offerings

Exhibit 85: Takeda Pharmaceutical Co. Ltd. – Key customers

Exhibit 86: Validation techniques employed for market sizing

Exhibit 87: Definition of market positioning of vendors


【レポート販売概要】

■ タイトル:マントル細胞リンパ腫治療法の世界市場:併用療法、単独療法
■ 英文:Global Mantle Cell Lymphoma Therapeutics Market 2019-2023
■ 発行日:2019年7月31日
■ 調査会社:Technavio
■ 商品コード:IRTNTR31758
■ 調査対象地域:アジア太平洋、ヨーロッパ、北米、その他
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。